Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Launched by BOEHRINGER INGELHEIM · Jul 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a medication called JARDIANCE® Tablets for people with chronic kidney disease (CKD). The goal is to see how well this medication works when taken daily over a long period in real-life situations, rather than just in a controlled clinical setting. The trial is currently looking for participants, and it welcomes individuals of all genders.

To be eligible for the study, participants must be diagnosed with CKD and have been prescribed JARDIANCE® Tablets specifically for this condition. Importantly, they should not have taken JARDIANCE® before, whether for kidney disease, type 2 diabetes, or chronic heart failure. Those who join the trial will contribute to important research that could help improve treatment options for people with CKD. Participants will need to give their written consent to take part in this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with CKD who are prescribed JARDIANCE® Tablets for CKD according to the current Japanese package insert and who provided written informed consent prior to enrolment in this study.
• • Patients who have never been treated with JARDIANCE® Tablets (including treatment for Type 2 diabetes mellitus (T2DM) and/or chronic heart failure (CHF)) before enrolment.
• Exclusion Criteria:
• • None